These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 35460902)

  • 1. Risk prediction models for hepatocellular carcinoma in chronic hepatitis B patients on antiviral therapy: A meta-analysis.
    Shen Y; Liu J; Han Z; Jiang W; Cui H; Xun Y
    Clin Res Hepatol Gastroenterol; 2022; 46(6):101930. PubMed ID: 35460902
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hepatocellular carcinoma prediction model performance decreases with long-term antiviral therapy in chronic hepatitis B patients.
    Wu X; Xu X; Zhou J; Sun Y; Ding H; Xie W; Chen G; Ma A; Piao H; Wang B; Chen S; Meng T; Ou X; Yang HI; Jia J; Kong Y; You H
    Clin Mol Hepatol; 2023 Jul; 29(3):747-762. PubMed ID: 37165622
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Assessing risk scores for predicting hepatocellular carcinoma in Thai patients with chronic hepatitis B.
    Kamalapirat T; Yingcharoen K; Ungtrakul T; Soonklang K; Dechma J; Chunnuan P; Kusuman P; Pothijaroen C; Tawpa J; Cheirsilpa K; Auewarakul C
    J Viral Hepat; 2021 Jul; 28(7):1034-1041. PubMed ID: 33880807
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hepatocellular Carcinoma Prediction Models in Chronic Hepatitis B: A Systematic Review of 14 Models and External Validation.
    Wu S; Zeng N; Sun F; Zhou J; Wu X; Sun Y; Wang B; Zhan S; Kong Y; Jia J; You H; Yang HI
    Clin Gastroenterol Hepatol; 2021 Dec; 19(12):2499-2513. PubMed ID: 33667678
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reassessing the accuracy of PAGE-B-related scores to predict hepatocellular carcinoma development in patients with chronic hepatitis B.
    Yip TC; Wong GL; Wong VW; Tse YK; Liang LY; Hui VW; Lee HW; Lui GC; Chan HL
    J Hepatol; 2020 May; 72(5):847-854. PubMed ID: 31857194
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term follow-up of cumulative incidence of hepatocellular carcinoma in hepatitis B virus patients without antiviral therapy.
    Jiang XY; Huang B; Huang DP; Wei CS; Zhong WC; Peng DT; Huang FR; Tong GD
    World J Gastroenterol; 2021 Mar; 27(11):1101-1116. PubMed ID: 33776376
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Risk prediction of hepatitis B virus-related hepatocellular carcinoma in the era of antiviral therapy.
    Wong GL; Wong VW
    World J Gastroenterol; 2013 Oct; 19(39):6515-22. PubMed ID: 24151375
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reporting and Performance of Hepatocellular Carcinoma Risk Prediction Models: Based on TRIPOD Statement and Meta-Analysis.
    Yang L; Wang Q; Cui T; Huang J; Jin H
    Can J Gastroenterol Hepatol; 2021; 2021():9996358. PubMed ID: 34513751
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Magnitude of and prediction for risk of hepatocellular carcinoma in patients with chronic hepatitis B taking entecavir or tenofovir therapy: A systematic review.
    Tseng CH; Tseng CM; Wu JL; Hsu YC; El-Serag HB
    J Gastroenterol Hepatol; 2020 Oct; 35(10):1684-1693. PubMed ID: 32343431
    [TBL] [Abstract][Full Text] [Related]  

  • 10. External validation of hepatocellular carcinoma risk scores in patients with chronic hepatitis B virus infection in China.
    Lou T; Li B; Xiong P; Jin C; Chen Y
    J Viral Hepat; 2021 Oct; 28(10):1373-1380. PubMed ID: 34218498
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Risk of hepatocellular carcinoma in antiviral treatment-naïve chronic hepatitis B patients treated with entecavir or tenofovir disoproxil fumarate: a network meta-analysis.
    Huang ZH; Lu GY; Qiu LX; Zhong GH; Huang Y; Yao XM; Liu XH; Huang SJ; Wu T; Yuan Q; Wang YB; Su YY; Zhang J; Xia NS
    BMC Cancer; 2022 Mar; 22(1):287. PubMed ID: 35300634
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Feasibility of dynamic risk prediction for hepatocellular carcinoma development in patients with chronic hepatitis B.
    Jeon MY; Lee HW; Kim SU; Kim BK; Park JY; Kim DY; Han KH; Ahn SH
    Liver Int; 2018 Apr; 38(4):676-686. PubMed ID: 28865176
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development of a scoring system to predict hepatocellular carcinoma in Asians on antivirals for chronic hepatitis B.
    Hsu YC; Yip TC; Ho HJ; Wong VW; Huang YT; El-Serag HB; Lee TY; Wu MS; Lin JT; Wong GL; Wu CY
    J Hepatol; 2018 Aug; 69(2):278-285. PubMed ID: 29551708
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prediction models of long-term cirrhosis and hepatocellular carcinoma risk in chronic hepatitis B patients: risk scores integrating host and virus profiles.
    Lee MH; Yang HI; Liu J; Batrla-Utermann R; Jen CL; Iloeje UH; Lu SN; You SL; Wang LY; Chen CJ;
    Hepatology; 2013 Aug; 58(2):546-54. PubMed ID: 23504622
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Risk score model for the development of hepatocellular carcinoma in treatment-naïve patients receiving oral antiviral treatment for chronic hepatitis B.
    Sohn W; Cho JY; Kim JH; Lee JI; Kim HJ; Woo MA; Jung SH; Paik YH
    Clin Mol Hepatol; 2017 Jun; 23(2):170-178. PubMed ID: 28506056
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effective viral suppression is necessary to reduce hepatocellular carcinoma development in cirrhotic patients with chronic hepatitis B: Results of a 10-year follow up.
    Zhang W; Wang X; Wang Y; Zhao X; Duan W; Wang Q; Wu X; Kong Y; Ma H; You H; Ou X; Jia J
    Medicine (Baltimore); 2017 Nov; 96(44):e8454. PubMed ID: 29095292
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serum fibrosis index-based risk score predicts hepatocellular carcinoma in untreated patients with chronic hepatitis B.
    Liang LY; Lee HW; Wong VW; Yip TC; Tse YK; Hui VW; Lui GC; Chan HL; Wong GL
    Clin Mol Hepatol; 2021 Jul; 27(3):499-509. PubMed ID: 33631920
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Four-year entecavir therapy reduces hepatocellular carcinoma, cirrhotic events and mortality in chronic hepatitis B patients.
    Su TH; Hu TH; Chen CY; Huang YH; Chuang WL; Lin CC; Wang CC; Su WW; Chen MY; Peng CY; Chien RN; Huang YW; Wang HY; Lin CL; Yang SS; Chen TM; Mo LR; Hsu SJ; Tseng KC; Hsieh TY; Suk FM; Hu CT; Bair MJ; Liang CC; Lei YC; Tseng TC; Chen CL; Kao JH;
    Liver Int; 2016 Dec; 36(12):1755-1764. PubMed ID: 27634134
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Twelve-month post-treatment parameters are superior in predicting hepatocellular carcinoma in patients with chronic hepatitis B.
    Ahn SB; Choi J; Jun DW; Oh H; Yoon EL; Kim HS; Jeong SW; Kim SE; Shim JJ; Cho YK; Lee HY; Han SW; Nguyen MH;
    Liver Int; 2021 Jul; 41(7):1652-1661. PubMed ID: 33550661
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HCC prediction models in chronic hepatitis B patients receiving entecavir or tenofovir: a systematic review and meta-analysis.
    Xu X; Jiang L; Zeng Y; Pan L; Lou Z; Ruan B
    Virol J; 2023 Aug; 20(1):180. PubMed ID: 37582759
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.